Nabla Bio
PrivateLast Round
Series C
Jun 17, 2025
Total Funding Raised
$107.38M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nabla Bio is a biotechnology company that develops an AI-driven platform for the rational design of developable, selective, and functional antibody therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nabla Bio Comparables
Compare Nabla Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 89% | |
| Evozyne | 85% | |
| Chan Zuckerberg Biohub | 85% |
Nabla Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 17, 2025 | ||||
| Series A | May 14, 2024 | ||||
| Seed | Dec 6, 2021 | ||||
| Grant | Apr 1, 2021 | ||||
| Accelerator | Aug 24, 2020 |
Nabla Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HV Capital | Series C |
| DST Global | Series C |
| Khosla Ventures | Series A, Seed |
| Cantos Ventures | Seed |
| Zetta Venture Partners | Series A, Seed |
| Pillar VC | Series A, Seed |
| Y Combinator | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2026
Grew 17% QoQ, from 23 to 27 employees.
- Jan 1, 2026
Received coverage in Science Magazine and Endpoints News.
Nabla Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nabla Bio's valuation, stock price, and market status.
Is Nabla Bio a public or private company?
Nabla Bio is a private company.
What is the current stock price of Nabla Bio?
Nabla Bio is a private company, so its shares have no public market price. Caplight tracks Nabla Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nabla Bio worth (valuation)?
Valuation information for Nabla Bio is not publicly available.
Can I buy Nabla Bio stock?
Nabla Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nabla Bio's last funding round?
Nabla Bio's most recent funding round was Series C on June 17, 2025.
Who are the main investors in Nabla Bio?
Key investors in Nabla Bio include HV Capital, Khosla Ventures, Zetta Venture Partners, Y Combinator, Radical Ventures.
Will Nabla Bio IPO soon?
No public IPO plans have been announced for Nabla Bio.
How can I track Nabla Bio secondary market activity?
Caplight tracks bids, offers, and trades in Nabla Bio's shares on secondary markets.